Studies on pharmacological activation of human immunoglobulin G by chemical modification and active subfragments. XIII. Effect of carboxamidemethylated Fc fragment (CM-Fc) on type II collagen-induced arthritis in DBA/1J mice.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  1994-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1248/BPB.17.623PMID 7920420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on pharmacological activation of human immunoglobulin G by chemical modification and active subfragments. XII. Effect of carboxamidemethylated Fc fragment (CM-Fc) from human immunoglobulin G on mixed lymphocyte reaction.

  1994cited by this paper
• Studies on pharmacological activation of human immunoglobulin G by chemical modification and active subfragments. X. Effect of carboxamidemethylated Fc fragment (CM-Fc) from human immunoglobulin G on delayed type hypersensitivity.

  1993cited by this paper
• Pathological evaluation of anti-rheumatic drugs on type II collagen-induced arthritis in DBA/1J mouse.

  1991cited by this paper
• Inhibition of collagen II-induced arthritis in mice--a comparison of the effects of Sch 24937, immunosuppressants and nonsteroidal antiinflammatory drugs on the clinical expression of disease.

  1990cited by this paper
• Isolation of T cell line capable of protecting mice against collagen-induced arthritis.

  1988cited by this paper
• Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen.

  1988cited by this paper
• Studies on type II collagen induced arthritis in mice

  1986cited by this paper
• Delayed type hypersensitivity (DTH) to type II collagen (CII) in DBA-1 mice.

  1986cited by this paper
• Characterization of monoclonal antibody specific for human type II collagen: possible implication in collagen-induced arthritis.

  1985cited by this paper
• Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus.

  1985cited by this paper
• Prostaglandin E2 regulation of tumoristatic factor production by macrophage-like P388D1 cells.

  1984cited by this paper
• Reconstitution of an inactive antigen-specific T cell suppressor factor by incubation of the factor with prostaglandins.

  1984cited by this paper
• Serum transfer of collagen-induced arthritis in mice

  1983cited by this paper
• Paradoxical effects of cyclosporin A on collagen arthritis in rats

  1983cited by this paper
• The induction of nonspecific T suppressor lymphocytes by prostaglandin E1.

  1981cited by this paper
• Influence of PGE on the immune response in melanoma-bearing mice.

  1980cited by this paper
• Some Statistical Methods Useful in Circulation Research

  1980cited by this paper
• Immunisation against heterologous type II collagen induces arthritis in mice

  1980cited by this paper
• Regulation of the immune response by prostaglandins.

  1980cited by this paper
• Suppression of immune complex vasculitis in rats by prostaglandin.

  1979cited by this paper
• A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells.

  1978cited by this paper
• Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats.

  1978cited by this paper
• Autoimmunity to type II collagen an experimental model of arthritis

  1977cited by this paper
• Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis.

  1977cited by this paper
• Effect of prostaglandin E 1 on adjuvant arthritis.

  1971cited by this paper
• Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats.

  1969cited by this paper

• [Induction of biological activities by chemically modified subfragments from human serum IgG and their application to development of medicine].

  1996cites this paper